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Abstract 
Background: Delayed intubation is associated with high mortality. There is a lack of objective criteria to decide the 
time of intubation. We assessed a recently described combined oxygenation index (ROX index) to predict intubation 
in immunocompromised patients. The study is a secondary analysis of randomized trials in immunocompromised 
patients, including all patients who received high‑flow nasal cannula (HFNC). The first objective was to evaluate the 
accuracy of the ROX index to predict intubation for patients with acute respiratory failure.
Results: In the study, 302 patients received HFNC. Acute respiratory failure was mostly related to pneumonia 
(n = 150, 49.7%). Within 2 (1–3) days, 115 (38.1%) patients were intubated. The ICU mortality rate was 27.4% (n = 83). 
At 6 h, the ROX index was lower for patients who needed intubation compared with those who did not [4.79 
(3.69–7.01) vs. 6.10 (4.48–8.68), p < 0.001]. The accuracy of the ROX index to predict intubation was poor [AUC = 0.623 
(0.557–0.689)], with low performance using the threshold previously found (4.88). In multivariate analysis, a higher 
ROX index was still independently associated with a lower intubation rate (OR = 0.89 [0.82–0.96], p = 0.04).
Conclusion: A ROX index greater than 4.88 appears to have a poor ability to predict intubation in immunocompro‑
mised patients with acute respiratory failure, although it remains highly associated with the risk of intubation and may 
be useful to stratify such risk in future studies.
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Background
In immunocompromised patients with acute respiratory 
failure (ARF), invasive mechanical ventilation remains 
associated with a high mortality rate [1]. Several oxygena-
tion strategies to avoid intubation have been tested in this 
setting. More recently, high-flow nasal cannula (HFNC) 
has been evaluated in non-immunocompromised 
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patients, resulting in an improved oxygenation ratio and 
reduced intubation rate, as shown in several recent meta-
analyses [2, 3]. In immunocompromised patients, the role 
of HFNC seems less clear, and a higher oxygenation rate 
does not translate into improved outcomes [4, 5]. Moreo-
ver, all these studies highlight the risk of delayed intuba-
tion, which is associated with a higher mortality rate [6]. 
Therefore, particular attention should be paid to the time 
of intubation to determine which patient would benefit 
from a non-invasive strategy of oxygenation [7]. So far, 
there is a lack of objective criteria to decide intubation, 
particularly within the first hours after the onset of the 
oxygenation strategy. Some recent studies have assessed 
several indices, including clinical and respiratory param-
eters [8, 9], such as the ROX index—including oxygen 
saturation  (SpO2), fraction of inspired oxygen  (FiO2), 
and respiratory rate (RR)—which is easy to use [10, 11]. 
A ROX index  (SpO2/FiO2/RR) over 4.88 within 2–12 h of 
starting HFNC was associated with a lower risk of intu-
bation. The area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve in the validation 
cohort was 0.703 (0.616–0.790) at 6 h and 0.752 (0.664–
0.840) at 12 h. However, the studies were carried out in 
non-immunocompromised patients with pneumonia-
related ARF. For immunocompromised patients, ARF 
aetiologies are numerous and response to HFNC could 
vary [7].
The aim of this study was to validate the ROX index in 
an external dataset, including only immunocompromised 
patients with ARF.
Methods
This is an ancillary study including two previous trials, 
IVNICTUS and HIGH [5, 12]. The IVNICTUS study, 
described elsewhere, evaluated an oxygenation strategy 
using non-invasive ventilation (NIV) versus oxygen in 
immunocompromised patients with ARF [12]. Oxygen 
could be maintained by HFNC in both groups. The HIGH 
study, also described elsewhere, compared oxygen versus 
high-flow nasal oxygen in immunocompromised patients 
with ARF [5]. In both studies, HFNC was used accord-
ing to recommendations (gas flow of 50–60 L/min,  FiO2 
adjusted for  SpO2 over 92%, temperature 37  °C). Insti-
tutional review board agreement and written informed 
consent were obtained from each patient or surrogate 
decision-maker (CPP Ile de France IV 2012/11SC and 
IDRCB: 2016-A00220-51). The inclusion criteria in both 
studies were ARF, defined by tachypnea over 30/min, 
respiratory distress (laboured breathing) and  SpO2 < 90% 
on room air at ICU admission. The non-inclusion crite-
ria were ARF being related to isolated cardiogenic pul-
monary oedema and invasive mechanical ventilation at 
ICU admission. Persistent hypoxemia or dyspnoea were 
among the intubation criteria.
The secondary analysis included all patients who 
received HFNC at least 6  h after randomization. The 
exclusion criteria for this secondary analysis were: do not 
intubate order, intubation before 6 h, and missed data on 
the ROX index at 6 h.
The ROX index  (SpO2/FiO2)/RR) was calculated at 6 h 
and also at 12  h for patients included from the IVNIC-
TUS study (the variable was not available in the HIGH 
study). Patient characteristics at ICU admission and out-
comes were also recorded.
The ARF aetiology was determined using the appropri-
ate diagnostic strategy and was classified as bacterial or 
viral pneumonia, opportunistic infection, lung involve-
ment by the underlying disease, drug-related pulmo-
nary toxicity, other identified cause, or undetermined 
aetiology. The diagnostic strategy and criteria for each 
diagnosis are described elsewhere [13]. Patients with 
ARF related to isolated cardiogenic oedema were not 
included in the trials [5, 12]. Radiographic patterns at 
ICU admission were described as 1–2 or 3–4 involved 
quadrants. The primary endpoint was the need for intu-
bation throughout the ICU stay. The primary objective 
was to assess the ability to discriminate between patients 
who would need intubation and patients who would not 
require intubation.
The secondary objective was to evaluate the ability of 
the ROX index to stratify intubation risk.
Statistical analyses
Results were expressed as median and 25th and 75th 
quartiles (Q1–Q3) for the quantitative data, and numbers 
and percentages for the categorical data. The quantitative 
variables were compared using the Student’s t test, or the 
Wilcoxon test in case of non-normal distribution. The 
qualitative variables were compared using the Chi-square 
test or Fisher’s exact test, as appropriate. Missing data 
were not imputed, and the number of analysed patients is 
described in each table in the results section.
Several analyses were carried out. The first was a uni-
variate analysis to describe the characteristics and out-
comes of intubated and non-intubated patients, while the 
second analysis assessed the predicting value of the ROX 
index for intubation using a ROC curve to discriminate 
between patients who needed intubation and those who 
had HFNC success. The thresholds found in a previous 
study were then evaluated for sensibility, specificity, like-
lihood positive ratio and likelihood negative ratio [10, 
11].
In a third analysis, the ROX index was adjusted with 
other variables associated with a high risk of intubation 
[14] that could be assessed during the first 24 h of ICU. 
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A multivariate logistic model was performed including 
characteristics at randomization (oxygen flow over 9 L/
min, study), ARF related to pneumonia and SOFA score 
at day 1. All clinically relevant variables decided a priori 
and those with a low level of missing data were included 
in the multivariate analysis, even in cases of non-signifi-
cant difference in the univariate analysis. The odds ratios 
(ORs) of variables present in the final model are given 
with their 95% confidence intervals (CI).
Several sensitivity analyses were performed
Firstly, a ROC curve analysis was performed to assess 
the accuracy of the multivariate model to discriminate 
between patients who would need intubation and those 
who would not. Secondly, in order to assess the impact 
of the ROX index, we assessed the predicting value of a 
modified multivariate model of intubation risk, exclud-
ing the ROX index, using a ROC curve to discriminate 
between patients who needed intubation and those who 
had HFNC success.
Thirdly, the risk stratification of the ROX index was 
then explored with the probability of intubation for each 
quartile of the ROX index.
Fourthly, one sensibility analysis was carried out 
excluding all patients who received NIV. In the INVIC-
TUS study [12], half of the patients were randomized to 
receive a NIV session immediately after randomization. 
Although the ROX index was calculated outside a NIV 
session, the NIV session may modified the risk of intuba-
tion, the RR and the  SpO2 at hour 6. To assess the impact 
of this device, we performed the same analysis excluding 
patients who received NIV.
The ROX index at 12 h was also analysed, where avail-
able (in the IVNICTUS cohort only).
All analyses were carried out using the R 3.3.3 statis-
tical software, and the statistical significance level was 
fixed at 0.05.
Results
This study included 302 patients admitted with ARF 
(Fig. 1). Patients were mostly male (n = 208, 68.9%), with 
a median age of 63 (55–70). The underlying disease was 
mostly haematological malignancy (n = 225, 74.5%), while 
ARF was related to viral or bacterial pneumonia (n = 150, 
49.7%), opportunistic pneumonia (n = 54, 17.9%), toxic-
ity or underlying disease (n = 26, 8.6%) and other mis-
cellaneous reasons (n = 52, 17.2%) including pulmonary 
embolism, extrapulmonary acute respiratory distress 
syndrome (ARDS), pleural effusion and atelectasis.
The oxygen flow needed at randomization was 10 
(7–15) L/min, and 166 (55%) patients required an oxygen 
flow over 9 L/min. Forty-five (14.9%) patients received 
NIV and HFNC. The RR was 27 (22–33)/min, 30  min 
after randomization. In the HIGH study, there were 
guidelines for HFNC use with at least 50 L/min [5]. In the 
IVNICTUS study, HFNC flow was 50 (35–50) L/min at 
initiation. For 122 (49.6%) patients, 3–4 quadrants were 
involved on the chest X-ray. The median ROX index at 
6 h was 5.62 (4.17–8.29).
Throughout the ICU stay, invasive mechanical ven-
tilation was required by 115 (38.1%) patients within the 
2 (1–3) days. The length of hospital stay was 24 (14–29) 
days, while the ICU mortality rate was 27.4% (n = 83). 
Table  1 summarizes patient characteristics at ICU 
admission and outcomes based on the need for invasive 
mechanical ventilation. The ROX index at 6 h was signifi-
cantly different between patients who required intuba-
tion and those who did not. The probability of intubation 
increased when the ROX index decreased (Fig. 2). Table 2 
describes patient characteristics according to the ROX 
index value (over or below 4.88).  
Prediction of intubation need using the ROX index at 6 h
Additional file 1: Figure S1 describes the ROC curve for 
the probability of intubation based on the ROX index in 
our cohort. The AUC was 0.623 (0.557–0.689). Using the 
threshold previously found (ROX index over 4.88 at 6 h, 
was associated with lower intubation rate) [11], the pre-
diction of intubation was very low (sensibility of 52.1%, 
specificity of 68.9%, positive likelihood ratio of 1.69 and 
negative likelihood ratio of 0.69). Also, using an ROX 
index below 3.47 [11], the prediction of HFNC failure 
had higher sensibility (90.9%) but a specificity of 21%, 
a positive predictive value of 65%, a negative predictive 
value of 59%, a positive likelihood ratio of 2.3 and a nega-
tive likelihood ratio of 0.86.
Adjusted ROX index at 6 h based on other risks 
of intubation
In a multivariate analysis that included patients’ charac-
teristics at admission (Table 3), a higher ROX index was 
still independently associated with a lower intubation rate 
(OR = 0.89 [0.82–0.96], p = 0.04). The SOFA score at day 
1 was associated with a higher risk of intubation. There 
was no interaction between SOFA J1 and ROX index. A 
modified model without SOFA day 1 did not modify the 
result on the ROX index [OR = 0.89 (0.83–0.96)].
Additional file 1: Figure S2 describes the probability of 
intubation according to the multivariable model includ-
ing the ROX index.
Sensibility analyses
Additional file  1: Figure S3 describes the ROC curve of 
the probability of intubation with an adjusted ROX index 
at 6  h. The AUC of this curve was 0.662 (0.596–0.729). 
This ROC curve was compared to the one from a model 
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including all variables a priori associated with intubation 
but without the ROX index at 6 h (Additional file 1: Fig-
ure S4). The AUC of this second ROC curve was 0.632 
(0.563–0.702). The model including ROX index showed a 
better overall fit (p = 0.002).
Additional file 1: Figure S5 describes the risk stratifica-
tion of intubation according to the quartile of the ROX 
index. The probability of intubation decreased with a 
high ROX index, without overlap between each quartile, 
leading to a good performance of risk stratification.
Statistical analysis of the impact of NIV was explored 
by excluding the patients who eventually received NIV 
within the first 6 h. The AUC of the ROC curve was 0.630 
(0.558–0.703). In the multivariate analysis, the ROX 
index at 6  h was still independently associated with a 
lower intubation rate [OR = 0.90 (0.82–0.97), p = 0.01]. 
In this secondary analysis, the SOFA score at day 1 was 
also associated with intubation [OR = 1.16 (1.06–1.27), 
p = 0.001].
Finally, in the IVNICTUS study, the ROX index was 
available for 89 out of 95 (93.6%) patients, among whom 
39 (43.8%) were intubated during the ICU stay after 12 h. 
The AUC of the ROC curve was 0.655 (0.538–0.772).
Discussion
In this study, the ROX index 6 h after HFNC onset had 
a poor performance in discriminating between patients 
who would be intubated or not, but this index could be 
a tool for risk stratification. Also, the ROX index was still 
associated with the risk of intubation, even when other 
significant predictors were included, such as the SOFA 
score [14].
Nevertheless, its accuracy to discriminate between 
patients who would need intubation and those who 
would receive only a non-invasive oxygenation strategy 
was very low, with low specificity and sensibility. In addi-
tion, the performance of a lower threshold (3.47) to pre-
dict HFNC failure was poor. Despite the low accuracy of 
Fig. 1 Flowchart
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this index to discriminate between patients who would 
ultimately need intubation or not, the ROX index can be 
easily recorded at the bedside. However, although RR, 
saturation and oxygen levels could be helpful for extreme 
values, the performance of these parameters to determine 
the intubation risk remains poor for medium values. 
Moreover, the ROX index at 6 h is a static measurement 
of clinical condition in ARF patients. Predicting intuba-
tion remains difficult and may depend on several condi-
tions. Apart from respiratory parameters, the decision to 
intubate would also be determined by other organ dys-
functions, particularly haemodynamic and neurological 
dysfunctions. Repeated measures of oxygenation may 
also be of importance [11]. Few studies included the 
neurological and haemodynamic status in their predic-
tive score [9]. Our study included ARF aetiology, oxygen 
needs at randomization and organ failure in the multi-
variate analysis, as these parameters have been associated 
with a risk of intubation [14]. Regarding the duration 
of oxygen needs and the assumed evolution of the dis-
ease, intubation would be necessary in the most severe 
patients and should not be delayed [6]. The physician’s 
experience could also influence the decision to intubate. 
As not all these characteristics can be included in a sole 
Table 1 Characteristics and outcomes based on the need for intubation
ARF: acute respiratory failure, NIV: non-invasive ventilation, RR: respiratory rate
Variables Patients who need 
intubation (n = 115)
Patients who were 
not intubated (n = 187)
p
Age (year) median, (IQR) 63 (53–69) 63 (56–71) 0.25
Gender, male (n, %) 81 (70) 127 (68) 0.74
Comorbidities (n, %)
 Cardiovascular 59 (58) 92 (56) 0.85
 Pulmonary 41 (40.6) 63 (38.7) 0.85
 Kidney 15 (15) 34 (21) 0.31
Charlson Index median, (IQR) missing data = 36 4 (3–6) 5 (4–7) 0.006
Underlying disease (n, %)
 Haematological malignancy, n (%) 90 (78) 135 (72) 0.12
Allogeneic stem cell transplant, n (%) 15 (14.7) 13 (9.3) 0.27
Performance status < 2 (n, %) 68 (59) 111 (59) 0.99
Number of quadrant involved = 3 or 4 (n, %) missing data = 56 56/96 (44) 66/150 (31) 0.04
Aetiology of ARF (n, %) 0.07
 Bacterial or viral pneumonia 58 (50) 92 (49.5)
 Opportunistic infection 27 (23.5) 27 (14.4)
 Lung involvement by the underlying disease drug‑related pulmonary 
toxicity
7 (6) 19 (10)
 Other identified causes 13 (11) 39 (21)
 No identified cause 9 (7.8) 8 (4.3)
Neutropenia recovery at admission (n, %) 15 (13) 13 (7) 0.12
SOFA day 1 missing data = 25 6 [3–9] 4 [2–6]  < 0.001
RR 30 min after randomization median, (IQR) missing data = 14 29 (22.5–35) 26 (22–32) 0.02
Oxygen flow > 9 L/min at randomization, n (%) 66 (57.4) 100 (53.5) 0.02
ROX index at H6 4.79 [3.69–7.01] 6.10 [4.48–8.68]  < 0.001
NIV group 20 (17.4) 25 (13.3) 0.43
Glasgow score at 15 at Day 1 (n,%) 97 (84) 160 (86) 0.86
Length between ICU admission and intubation 2 (1–3) NA NA
Outcomes
 Vasopressor during ICU stay, n (%) 99 (86) 34 (18)  < 0.001
 Renal replacement therapy during ICU stay, n (%) 38 (33) 11 (6)  < 0.001
 End of life decision during ICU stay, n (%) 31 (29) 10 (5.4)  < 0.001
 ICU mortality (n,%) 64 (55.7) 19 (10.2)  < 0.001
Length of ICU stay for survival patient (n = 219) 17 (12.5–27) 7 (5–11)  < 0.001
Length of hospital stay median, (IQR) (n = 302) 32 (15–60) 21 (13–32) 0.001
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oxygenation index, this contributes to the poor accuracy 
of the ROX index to discriminate between patients who 
would need intubation and those who would not.
Moreover, the ROX index is a single measure and may 
not reflect the clinical evolution of a patient. With the 
sensitivity analysis at 12  h, we explored a second ROX 
index value, but this was also only a static measure-
ment. Mauri et al. assessed the response to different lev-
els of gas flow [15]; interestingly, they found a subgroup 
of patients where the ROX index of the most severe one 
rose within 20  min of increasing the gas flow on the 
HFNC. It is possible that a higher gas flow could increase 
lung recruitment. These changes highlighted the diffi-
culty of determining a sole oxygenation index to distin-
guish between patients who would need intubation and 
those who would not. Roca et  al. suggested a repeated 
measurement of the ROX index to increase its accuracy 
[11]. Also, this result identified the need for a scalable 
variable to detect a worsening outcome. Probably only 
the analysis of a large dataset could determine the profile 
of a patient who would need intubation.
According to our study, more than accuracy to discrim-
inate between patients who need intubation or not, the 
ROX index may have a good performance for risk strati-
fication [16]. Contrary to the limited clinical application 
of the ROX index itself, the stratification in low, interme-
diate and high-risk patients may be helpful for the early 
identification of patients who would fail the HFNC trial 
in further studies. Such results should be confirmed in 
further studies.
This study has several limitations. Firstly, it was a ret-
rospective analysis of data, and the reason for intubation 
was not described. Although intubation occurred within 
the first days of ICU admission, a later intubation may not 
be related to the ROX index value at 6 h. Moreover, 108 
patients could not be included in this analysis because 
of missing data. Those patients might have modified the 
conclusion. However, the study included a high number 
of patients, as in previous studies on the ROX index [11].
Secondly, this external validation cohort included 
only immunocompromised patients. Indeed, different 
aetiology of ARF [13], different oxygenation needs and 
Fig. 2 Probability of intubation according the ROX index
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different comfort related to the device [17] in immuno-
compromised patients may have modified the response 
to HFNC and, consequently, the ROX index accuracy.
Thirdly, we could not analyse the need for a vasopres-
sor or other organ failure supply before intubation. Only 
the SOFA score at day 1 was analysed, even in cases 
of intubation. This may be a major limitation, because 
some patients would display haemodynamic instability 
after intubation. However, we did not detect any inter-
action between the ROX index and the SOFA day 1 
score. Only prospective data could provide a remedy to 
this point.
Fourthly, some patients received NIV within the first 
6  h. Those NIV sessions could have increased lung 
recruitment and modified the ROX index. However, 
the sensibility analysis excluding those patients did not 
show any difference, and the ROX index remained asso-
ciated with the risk of intubation.
Fifth, unlike previous studies [11], several ARF aeti-
ologies were included in our research. In the setting of 
immunocompromised patients, the length of oxygen 
needs and the severity of ARF may vary according to 
the ARF aetiology. However, half of patients had bacte-
rial pneumonia.
Table 2 Characteristics and outcomes based on ROX index over or under 4.88
Variables Patients with ROX index 
H6 > 4.88 (n = 184)
Patients with ROX index 
H6 ≤ 4.88 (n = 118)
p
Age (year) median, (IQR) 63.5 (55–71) 63 (54–69) 0.57
Gender, male (n, %) 130 (71) 78 (66) 0.48
Comorbidities (n, %)
 Cardiovascular 93 (58) 58 (56) 0.8
 Pulmonary 61 (38) 43 (41) 0.69
 Renal 28 (18) 21 (20) 0.72
Charlson Index median, (IQR) missing data = 36 5 (4–7) 5 (3–6) 0.42
Underlying disease (n, %)
 Haematological malignancy, n (%) 139 (75) 86 (73) 0.36
Allogeneic stem cell transplant, n (%) 19 (11) 9 (8) 0.56
Performance status > 2 (n, %) 63 (34) 42 (36) 0.13
Number of quadrant involved = 3 or 4 (n,%) missing data = 56 68 (45) 54 (57) 0.09
Aetiology of ARF (n, %) 0.84
 Bacterial or viral pneumonia 92 (50) 58 (49)
 Opportunistic infection 29 (16) 25 (21)
 Lung involvement by the underlying disease Drug‑related pulmonary 
toxicity
16 (9) 10 (8)
 Other identified causes 33 (18) 19 (16)
 No identified cause 12 (6) 5 (4)
Neutropenia recovery at admission (n,%) 18 (10) 7 (6) 0.33
SOFA day 1 missing data = 25 4 (2–7) 4.5 (2–7) 0.94
RR 30 min after randomization median, (IQR) missing data = 14 25 (21–30) 31 (25–35)  < 0.001
Oxygen flow > 9 L/min at randomization, n (%) 94 (51) 72 (13) 0.49
NIV group 30 (16) 15 (13) 0.45
Glasgow score at 15 at Day 1 (n, %) 160 (87) 97 (82) 0.52
Outcomes
 Intubated during ICU (n, %) 55 (30) 60 (51)  < 0.001
 Length between ICU admission and intubation 3 (1–4.5) 2 (1–2.5) 0.005
 Vasopressor during ICU stay, n (%) 71 (39) 62 (52) 0.03
Renal Replacement Therapy during ICU stay, n (%) 30 (16) 19 (16) 0.32
 End of life decision during ICU stay, n (%) 47 (26) 47 (36) 0.02
 Day 28 mortality (n,%) 39 (21) 44 (37) 0.003
Length of ICU stay, median (IQR) survival patient (n = 219) 8 (5–13) 10 (6–17.7) 0.02
Length of hospital stay median, (IQR) (n = 302 24 (15–38) 22 (12–40) 0.52
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Conclusion
Although the ROX index appears to have a low per-
formance in predicting intubation among immuno-
compromised patients with acute respiratory failure, it 
still represents one of the strongest associated factors 
with intubation. More data including non-respiratory 
parameters may be included in further prospective 
cohorts to confirm these results. However, the index 
seems to have a good performance for risk stratification 
and may be useful for further studies.
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